Fairmount Funds Management, a fund management company, led a $91m Series A funding round in miRagen Therapeutics, a biotechnology company. The round was also joined by Venrock, BVF Partners, Cormorant Asset Management, Perceptive Advisors, Wellington Management, Ally Bridge Group, Logos Capital, Surveyor Capital, Commodore Capital, and Ridgeback Capital. The proceeds from the private placement are intended to be used primarily to advance clinical studies of VRDN-001, a clinical-stage insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) in development for thyroid eye disease.